Company news

Cue Biopharma, Inc. news in 2023

Cue Biopharma, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 8, 2023

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

November 2, 2023

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 26, 2023

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

September 25, 2023

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 8, 2023

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2023

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 8, 2023

Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

April 24, 2023

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

April 11, 2023

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

March 20, 2023

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

February 21, 2023

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

February 15, 2023

Cue Biopharma Announces Chief Medical Officer Transition

January 22, 2023

Calls in 2023

Decks in 2023